Pre-treatment inflammatory parameters predict survival from endometrial cancer: a prospective database analysisCitation formats

Standard

Pre-treatment inflammatory parameters predict survival from endometrial cancer: a prospective database analysis. / Njoku, Kelechi; Ramchander, Neal C; Wan, Louise; Barr, Chloe; Crosbie, Emma.

In: Gynecologic Oncology, 12.11.2021.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{39cf187c13be4262b3a9a54a961a5d81,
title = "Pre-treatment inflammatory parameters predict survival from endometrial cancer: a prospective database analysis",
abstract = "Purpose: Inflammation predisposes to tumorigenesis by damaging DNA, stimulating angiogenesis and potentiating pro-proliferative and anti-apoptotic processes. The aim of this study was to investigate whether pre-treatment biomarkers of systemic inflammation are associated with survival outcomes in endometrial cancer.Patients and methods: Women with endometrial cancer were recruited to a prospective database study. Pre-treatment systemic markers of inflammation, including C-reactive protein (CRP), Glasgow Prognostic Score and lymphocyte-based ratios [neutrophil-lymphocyte ratio (NMR), monocyte-lymphocyte ratio (MLR), systemic immune-inflammation index (SII)], were analysed in relation to overall, endometrial cancer-specific and recurrence-free survival using Kaplan-Meier estimation and multivariable Cox regression.Results: In total, 522 women of mostly White British ethnicity, with a median age of 66 years (interquartile range (IQR), 56, 73) and BMI of 32kg/m2 (IQR 26, 39) were included in the analysis. Most had low-grade (67.2%), early-stage (85.4% stage I/II), endometrioid (74.5%) tumors. Women with pre-treatment CRP ≥5.5mg/L had a 68% increase in overall (adjusted HR=1.68, 95% CI 1.00-2.81, p=0.049) and a two-fold higher cancer-specific mortality risk than those with CRP <5.5mg/L (adjusted HR=2.04, 95%CI 1.03-4.02, p=0.04). Absolute lymphocyte count, NLR, MLR and SII were associated with adverse clinico-pathologic factors, but not overall, cancer-specific or recurrence-free survival in the multivariable analysis.Conclusion: If confirmed in an independent cohort, CRP may offer a simple, low-cost test to refine pre-treatment risk assessment and guide personalised care in endometrial cancer. Our participants were mostly of White British ethnicity and further studies are needed to confirm the utility of CRP as a prognostic biomarker in other populations. ",
author = "Kelechi Njoku and Ramchander, {Neal C} and Louise Wan and Chloe Barr and Emma Crosbie",
year = "2021",
month = nov,
day = "12",
language = "English",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - Pre-treatment inflammatory parameters predict survival from endometrial cancer: a prospective database analysis

AU - Njoku, Kelechi

AU - Ramchander, Neal C

AU - Wan, Louise

AU - Barr, Chloe

AU - Crosbie, Emma

PY - 2021/11/12

Y1 - 2021/11/12

N2 - Purpose: Inflammation predisposes to tumorigenesis by damaging DNA, stimulating angiogenesis and potentiating pro-proliferative and anti-apoptotic processes. The aim of this study was to investigate whether pre-treatment biomarkers of systemic inflammation are associated with survival outcomes in endometrial cancer.Patients and methods: Women with endometrial cancer were recruited to a prospective database study. Pre-treatment systemic markers of inflammation, including C-reactive protein (CRP), Glasgow Prognostic Score and lymphocyte-based ratios [neutrophil-lymphocyte ratio (NMR), monocyte-lymphocyte ratio (MLR), systemic immune-inflammation index (SII)], were analysed in relation to overall, endometrial cancer-specific and recurrence-free survival using Kaplan-Meier estimation and multivariable Cox regression.Results: In total, 522 women of mostly White British ethnicity, with a median age of 66 years (interquartile range (IQR), 56, 73) and BMI of 32kg/m2 (IQR 26, 39) were included in the analysis. Most had low-grade (67.2%), early-stage (85.4% stage I/II), endometrioid (74.5%) tumors. Women with pre-treatment CRP ≥5.5mg/L had a 68% increase in overall (adjusted HR=1.68, 95% CI 1.00-2.81, p=0.049) and a two-fold higher cancer-specific mortality risk than those with CRP <5.5mg/L (adjusted HR=2.04, 95%CI 1.03-4.02, p=0.04). Absolute lymphocyte count, NLR, MLR and SII were associated with adverse clinico-pathologic factors, but not overall, cancer-specific or recurrence-free survival in the multivariable analysis.Conclusion: If confirmed in an independent cohort, CRP may offer a simple, low-cost test to refine pre-treatment risk assessment and guide personalised care in endometrial cancer. Our participants were mostly of White British ethnicity and further studies are needed to confirm the utility of CRP as a prognostic biomarker in other populations.

AB - Purpose: Inflammation predisposes to tumorigenesis by damaging DNA, stimulating angiogenesis and potentiating pro-proliferative and anti-apoptotic processes. The aim of this study was to investigate whether pre-treatment biomarkers of systemic inflammation are associated with survival outcomes in endometrial cancer.Patients and methods: Women with endometrial cancer were recruited to a prospective database study. Pre-treatment systemic markers of inflammation, including C-reactive protein (CRP), Glasgow Prognostic Score and lymphocyte-based ratios [neutrophil-lymphocyte ratio (NMR), monocyte-lymphocyte ratio (MLR), systemic immune-inflammation index (SII)], were analysed in relation to overall, endometrial cancer-specific and recurrence-free survival using Kaplan-Meier estimation and multivariable Cox regression.Results: In total, 522 women of mostly White British ethnicity, with a median age of 66 years (interquartile range (IQR), 56, 73) and BMI of 32kg/m2 (IQR 26, 39) were included in the analysis. Most had low-grade (67.2%), early-stage (85.4% stage I/II), endometrioid (74.5%) tumors. Women with pre-treatment CRP ≥5.5mg/L had a 68% increase in overall (adjusted HR=1.68, 95% CI 1.00-2.81, p=0.049) and a two-fold higher cancer-specific mortality risk than those with CRP <5.5mg/L (adjusted HR=2.04, 95%CI 1.03-4.02, p=0.04). Absolute lymphocyte count, NLR, MLR and SII were associated with adverse clinico-pathologic factors, but not overall, cancer-specific or recurrence-free survival in the multivariable analysis.Conclusion: If confirmed in an independent cohort, CRP may offer a simple, low-cost test to refine pre-treatment risk assessment and guide personalised care in endometrial cancer. Our participants were mostly of White British ethnicity and further studies are needed to confirm the utility of CRP as a prognostic biomarker in other populations.

M3 - Article

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

ER -